Cord Blood Brain Derived Neurotrophic Factor: Diagnostic and Prognostic Marker in Fullterm Newborns with Perinatal Asphyxia

Imam, Safaa S.; Gad, Ghada I.; Atef, Shereen H.; Shawky, Mohamed

doi:10.3923/pjbs.2009.1498.1504

Cited by 24 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic serum BDNF may be reflective of injury severity and serve as a potential biomarker for tracking treatment response and effectiveness in real-time (Failla et al, 2016 ). If serum BDNF levels are persistently elevated in neonates with HIE this suggests severe brain injury and a poor prognosis (Imam et al, 2009 ).…”

Section: Brain-derived Neurotrophic Factor (Bdnf)mentioning

confidence: 99%

See 1 more Smart Citation

Blood Biomarkers for Evaluation of Perinatal Encephalopathy

et al. 2016

View full text Add to dashboard Cite

Recent research in identification of brain injury after trauma shows many possible blood biomarkers that may help identify the fetus and neonate with encephalopathy. Traumatic brain injury shares many common features with perinatal hypoxic-ischemic encephalopathy. Trauma has a hypoxic component, and one of the 1st physiologic consequences of moderate-severe traumatic brain injury is apnea. Trauma and hypoxia-ischemia initiate an excitotoxic cascade and free radical injury followed by the inflammatory cascade, producing injury in neurons, glial cells and white matter. Increased excitatory amino acids, lipid peroxidation products, and alteration in microRNAs and inflammatory markers are common to both traumatic brain injury and perinatal encephalopathy. The blood-brain barrier is disrupted in both leading to egress of substances normally only found in the central nervous system. Brain exosomes may represent ideal biomarker containers, as RNA and protein transported within the vesicles are protected from enzymatic degradation. Evaluation of fetal or neonatal brain derived exosomes that cross the blood-brain barrier and circulate peripherally has been referred to as the “liquid brain biopsy.” A multiplex of serum biomarkers could improve upon the current imprecise methods of identifying fetal and neonatal brain injury such as fetal heart rate abnormalities, meconium, cord gases at delivery, and Apgar scores. Quantitative biomarker measurements of perinatal brain injury and recovery could lead to operative delivery only in the presence of significant fetal risk, triage to appropriate therapy after birth and measure the effectiveness of treatment.

show abstract

Section: Brain-derived Neurotrophic Factor (Bdnf)mentioning

confidence: 99%

“…Because activin responds to oxidative challenge protecting neurons, it may have a role as a potential therapy in stroke injury (Mukerji et al, 2007 ). In full term neonates with moderate to severe HIE, activin A is significantly elevated in CSF, and it may be a reliable early indicator for the identification of HIE (Imam et al, 2009 ).…”

Section: Activin Amentioning

confidence: 99%

Blood Biomarkers for Evaluation of Perinatal Encephalopathy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…BDNF supports the survival of existing neurons and encourages the growth and differentiation of new neurons and synapses. Imam et al (2009) described higher cord plasma BDNF levels in newborns with HIE when compared with control neonates. These elevated BDNF levels predicted poor neurologic outcomes.…”

Section: Hypoxic-ischemic Encephalopathymentioning

confidence: 99%

Biomarkers of Hypoxic-Ischemic Encephalopathy in Newborns

Douglas-Escobar¹,

Weiss²

2012

Front. Neur.

View full text Add to dashboard Cite

As neonatal intensive care has evolved, the focus has shifted from improving mortality alone to an effort to improve both mortality and morbidity. The most frequent source of neonatal brain injury occurs as a result of hypoxic-ischemic injury. Hypoxic-ischemic injury occurs in about 2 of 1,000 full-term infants and severe injured infants will have lifetime disabilities and neurodevelopmental delays. Most recently, remarkable efforts toward neuroprotection have been started with the advent of therapeutic hypothermia and a key step in the evolution of neonatal neuroprotection is the discovery of biomarkers that enable the clinician-scientist to screen infants for brain injury, monitor progression of disease, identify injured brain regions, and assess efficacy of neuroprotective clinical trials. Lastly, biomarkers offer great hope identifying when an injury occurred shedding light on the potential pathophysiology and the most effective therapy. In this article, we will review biomarkers of HIE including S100B, neuron specific enolase, umbilical cord IL-6, CK-BB, GFAP, myelin basic protein, UCHL-1, and pNF-H. We hope to contribute to the awareness, validation, and clinical use of established as well as novel neonatal brain injury biomarkers.

show abstract

“…This study also demonstrated decreased BDNF expression in all asphyxiated newborns. Previously, in studies of asphyxiated human newborns, increased BDNF levels have been found in cord blood at birth [ 57 ], blood serum 24 hours after birth [ 58 ], and cerebrospinal fluid [ 59 ], with the degree of increased expression correlated to brain injury severity [ 58 ]. Increased brain BDNF expression was also found in a rat model of neonatal hypoxia-ischemia [ 60 ].…”

Section: Discussionmentioning

confidence: 99%

Angiogenesis Dysregulation in Term Asphyxiated Newborns Treated with Hypothermia

et al. 2015

View full text Add to dashboard Cite

BackgroundNeonatal encephalopathy following birth asphyxia is a major predictor of long-term neurological impairment. Therapeutic hypothermia is currently the standard of care to prevent brain injury in asphyxiated newborns but is not protective in all cases. More robust and versatile treatment options are needed. Angiogenesis is a demonstrated therapeutic target in adult stroke. However, no systematic study examines the expression of angiogenesis-related markers following birth asphyxia in human newborns.ObjectiveThis study aimed to evaluate the expression of angiogenesis-related protein markers in asphyxiated newborns developing and not developing brain injury compared to healthy control newborns.Design/MethodsTwelve asphyxiated newborns treated with hypothermia were prospectively enrolled; six developed eventual brain injury and six did not. Four healthy control newborns were also included. We used Rules-Based Medicine multi-analyte profiling and protein array technologies to study the plasma concentration of 49 angiogenesis-related proteins. Mean protein concentrations were compared between each group of newborns.ResultsCompared to healthy newborns, asphyxiated newborns not developing brain injury showed up-regulation of pro-angiogenic proteins, including fatty acid binding protein-4, glucose-6-phosphate isomerase, neuropilin-1, and receptor tyrosine-protein kinase erbB-3; this up-regulation was not evident in asphyxiated newborns eventually developing brain injury. Also, asphyxiated newborns developing brain injury showed a decreased expression of anti-angiogenic proteins, including insulin-growth factor binding proteins -1, -4, and -6, compared to healthy newborns.ConclusionsThese findings suggest that angiogenesis pathways are dysregulated following birth asphyxia and are putatively involved in brain injury pathology and recovery.

show abstract

Cord Blood Brain Derived Neurotrophic Factor: Diagnostic and Prognostic Marker in Fullterm Newborns with Perinatal Asphyxia

Abstract: AbstractsConclusions Abnormal aEEG finding in infants with severe hyperbilirubinemia is useful for detection of asymptomatic BIND and can be reversible with appropriate treatment. ENIGMA OF MANAGEMENT OF SEIZURES IN HYPOXIC ISCHEMIC ENCEPHALOPATHY (HIE) -

Cited by 24 publications

References 9 publications

Blood Biomarkers for Evaluation of Perinatal Encephalopathy

Blood Biomarkers for Evaluation of Perinatal Encephalopathy

Biomarkers of Hypoxic-Ischemic Encephalopathy in Newborns

Angiogenesis Dysregulation in Term Asphyxiated Newborns Treated with Hypothermia

Contact Info

Product

Resources

About